ncRNA basic information
ncRNA ID:
MI0000446/MI0000470
ncRNA Database:
miRBase
ncRNA Name:
miR-125b
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-PCR
ncRNA Target Gene:
HER2
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
In this study, the potential function of miR-125b on DDP resistance in gastric cancer cells was investigated. Sixteen miRNAs significantly differential expressed in gastric tumor tissues and adjacent tissues were characterized and their corresponding putative target genes were also screened. MiR-125b was selected as our focus for its evident down-regulated expression among candidate genes. Real-time polymerase chain reaction assay indicated that miR-125b was significantly down-regulated in gastric cancer tissues and various cell lines. HER2 was identified as a target gene of miR-125b by dual luciferase reporter assay and Western blot. Moreover, miR-125b overexpression inhibited not only the proliferation, migration, and invasion abilities of HGC-27 and MGC-803 cells, but also in vivo tumor growth of MGC-803 cells by an intratumoral delivery approach. Notably, we observed up-regulated miR-125b contributed to the chemosensitivity of DDP in HGC-27 and MGC-803 cells at different concentrations and also possessed sensibilization for DDP at different times. MiR-125b expression was found to be related to lymph node metastasis, HER2 expression and overall survival of patients through correlation analysis.
Drug Response:
sensitive
Cancer basic information
Cancer:
stomach cancer
Tissue/Cell:
cell line (GES-1, 293TN,HGC-27, MGC-803, AGS, N87, MKN-45, SGC-7901, BGC-823)
Other information
Title:
The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin.
Journal:
Oncotarget
Published:
2017
PubMed ID:
29416757